By Fineline Cube 
Dizal Pharmaceutical Co., Ltd. (SHA: 688192) announced that China’s Center for Drug Evaluation (CDE) has accepted for review and granted priority review status to its supplemental indication filing for Zegfrovy (sunvozertinib) as a first-line treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations. The filing is supported by positive results from the international Phase III WU-KONG28 confirmatory study.
Regulatory Filing Summary
| Component | Detail |
|---|---|
| Company | Dizal Pharmaceutical Co., Ltd. (SHA: 688192) |
| Product | Zegfrovy (sunvozertinib) – oral, irreversible, highly selective EGFR TKI |
| Regulatory Authority | Center for Drug Evaluation (CDE), China |
| Indication | First-line treatment of EGFR exon20ins NSCLC |
| Review Status | Accepted with priority review designation |
| Supporting Trial | Phase III WU-KONG28 international multicenter study |
| Primary Endpoint | Progression-free survival (PFS) vs. platinum-based doublet chemotherapy |
Molecular Profile & Clinical Differentiation
- Mechanism: Oral, irreversible, highly selective EGFR tyrosine kinase inhibitor (TKI)
- Target Spectrum: Multiple EGFR mutation subtypes, with specific activity against exon 20 insertion mutations
- Current Approvals:
- China: Second-line and later-line treatment for EGFR exon20ins NSCLC
- United States: Later-line treatment for EGFR exon20ins NSCLC
- Therapeutic Advance: Potential expansion to first-line setting represents significant clinical advancement
- Administration: Oral dosing regimen enabling outpatient treatment
Phase III WU-KONG28 Trial Results
| Study Design Element | Detail |
|---|---|
| Trial Type | Open-label, randomized, controlled, international multicenter Phase III |
| Patient Population | First-line EGFR exon20ins NSCLC |
| Comparator | Platinum-based doublet chemotherapy (standard of care) |
| Primary Endpoint | Progression-free survival (PFS) |
| Key Result | Statistically significant and clinically meaningful PFS improvement with sunvozertinib |
| Trial Status | Primary endpoint met, supporting regulatory filing |
The WU-KONG28 trial represents the first Phase III study to demonstrate superior efficacy of a targeted EGFR TKI over chemotherapy in the first-line EGFR exon20ins NSCLC setting.
Unmet Medical Need Addressed
| Clinical Challenge | Zegfrovy Solution |
|---|---|
| Limited First-Line Options | Targeted therapy specifically designed for EGFR exon20ins mutations |
| Chemotherapy Toxicity | Oral targeted therapy with potentially improved safety profile |
| Poor Outcomes with Standard Care | Significant PFS benefit demonstrated in Phase III trial |
| Mutation-Specific Treatment Gap | Highly selective inhibition addresses unique biology of exon20ins mutations |
| Treatment Sequencing | Establishes foundation for optimal treatment pathway in EGFR exon20ins NSCLC |
EGFR exon20 insertion mutations represent approximately 4-10% of all EGFR-mutated NSCLC cases and have historically been resistant to first-generation EGFR TKIs.
Competitive Landscape & Market Impact
- First-Line Opportunity: Addresses substantial unmet need in previously untreated EGFR exon20ins NSCLC patients
- Regulatory Advantage: Priority review status accelerates potential approval timeline in China
- Global Strategy: Building on existing approvals in China and U.S. for later-line indications
- Market Differentiation: Only EGFR TKI with Phase III data demonstrating first-line superiority over chemotherapy
- Commercial Potential: Premium positioning justified by clinical benefit and targeted mechanism
Strategic Significance for Dizal
- Portfolio Expansion: Extends Zegfrovy’s market opportunity from later-line to first-line setting
- Clinical Validation: Phase III success reinforces Dizal’s oncology development capabilities
- Revenue Growth: First-line indication significantly expands addressable patient population
- Global Recognition: International trial design supports potential regulatory submissions in additional markets
- Innovation Leadership: Positions Dizal as leader in addressing challenging EGFR mutation subtypes
Forward-Looking Statements
This brief contains forward-looking statements regarding Dizal Pharmaceutical’s Zegfrovy regulatory prospects, including CDE review timelines, potential approval outcomes, and commercial expectations. Actual results may differ due to risks including regulatory decisions, competitive developments, market adoption challenges, and evolving treatment guidelines for EGFR exon20ins NSCLC.-Fineline Info & Tech